Verification Opinion of China International Capital Corporation on Beijing Ruimait Medical Technology Co., Ltd.'s Expected Routine Related Transactions for 2026
China International Capital Corporation (hereinafter referred to as "CICC" or "Sponsor") is the sponsor for the initial public offering and ongoing supervision of Beijing Ruimait Medical Technology Co., Ltd. (hereinafter referred to as "Ruimait" or "Company"). In accordance with relevant laws, regulations, and normative documents, CICC has conducted a verification of Ruimait's expected routine related transactions for 2026, with the details as follows:
I. Basic Information on Routine Related Transactions
(1) Overview of Routine Related Transactions
Based on the needs of daily operations, Ruimait and its subsidiaries expect to engage in routine related transactions with related parties Chengdu Luozhi Technology Co., Ltd. (hereinafter referred to as "Chengdu Luozhi"), Shenzhen Deda Xing Drive Technology Co., Ltd. (hereinafter referred to as "Shenzhen Deda Xing"), and Delaisen (Beijing) Medical Technology Co., Ltd. (hereinafter referred to as "Delaisen") in 2026, with a total expected amount not exceeding 41 million yuan. The amount of routine related transactions between the company and the aforementioned related parties in 2025 was 17.8779 million yuan. On April 22, 2026, the 19th meeting of the third board of directors of the company reviewed and approved the proposal on the expected routine related transactions for 2026, with director Zhuang Zhi abstaining from voting on the proposal due to his related party status. Prior to submission to the board, the proposal was reviewed by a special meeting of independent directors, who unanimously agreed to submit it for board review. According to the Shenzhen Stock Exchange's rules and the articles of association of Beijing Ruimait Medical Technology Co., Ltd., the expected amount of this routine related transaction is within the decision-making authority of the board and does not require submission to the shareholders' meeting for review.
(2) Expected Categories and Amounts of Routine Related Transactions for 2026
| Transaction Category | Related Party | Transaction Content | Pricing Principle | Expected Amount (10,000 yuan) | Amount Transacted as of March 31 | Expected Amount for 2025 | Actual Amount for Last Year | Proportion of Last Year’s Amount in Similar Business | Reasons for Significant Differences |
|---|---|---|---|---|---|---|---|---|---|
| Purchase of goods, leasing, and other services | Chengdu Luozhi Technology Co., Ltd. | Purchase of goods, leasing, and other services | Fair pricing based on market price | 2000.00 | 53.18 | 1000.00 | 608.55 | 1.17% | Adjusted based on actual business needs |
| Purchase of goods and services | Shenzhen Deda Xing Drive Technology Co., Ltd. | Purchase of goods and services | Fair pricing based on market price | 2000.00 | 83.89 | 2800.00 | 1179.24 | 2.26% | Adjusted based on actual business needs |
| Purchase of goods and services | Delaisen (Beijing) Medical Technology Co., Ltd. | Purchase of goods and services | Fair pricing based on market price | 100.00 | 0 | 500.00 | 0 | 0 | No domestic business conducted, no related transactions occurred |
| Total | - | - | - | 4100.00 | 137.07 | 4300.00 | 1787.79 | - | - |
Note 1: The proportion of last year's amount is calculated based on the audited amount of similar business for the company in 2025.